18-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Hemophilia Treatment Market By Product (Desmopressin, Antifibrinolytic Agents, Plasma Derived Coagulation Factor Concentrates and Recombinant Coagulation Factor Concentrates), By Disease (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, and Antibody Therapy), By Treatment Type (On-demand and Prophylaxis), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region: Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global hemophilia treatment market in 2019 exceeded USD 14,000 Million. The market is expected to grow at a CAGR of around 15% and is anticipated to surpass USD 35,000 Million by 2026.
Hemophilia is a rare hereditary disease that leads to prolonged bleeding followed by an injury or surgery, as the disorder retards the blood coagulation property. This may lead to serious complications owing to internal bleeding in muscles, joints, and other organs such as the brain. In this condition, the levels of special proteins (blood clotting factors) drop significantly in the blood. Hemophilia A and hemophilia B are the two major variants of the disorder, of which, around 75% of the patient pool is suffering from the former variant of the disease. However, hemophilia can be acquired in the postnatal and adult stages when a patient’s immune system starts producing antibodies against the self-epitope, i.e. the plasma coagulation factor. The key treatment for hemophilia involves the development of substitutive coagulating factors that recover the blood’s coagulation property, thereby propelling the global hemophilia treatment market. However, there are no drugs available in the market that can completely cure the disorder and the genetic-based treatments, such as gene therapy, is quite expensive. All the aforementioned key factors are restraining the global hemophilia treatment market.
Browse the full “Hemophilia Treatment Market By Product (Desmopressin, Antifibrinolytic Agents, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates), By Disease (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, and Antibody Therapy), By Treatment Type (On-demand and Prophylaxis), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region: Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790
The hemophilia treatment across the globe is majorly conducted through plasma-derived coagulation factor concentrates
Under the product segment, plasma-derived coagulation factor concentrates is extensively used to treat hemophilia worldwide as the product is considered to significantly boost the coagulation cascade even in the absence or low levels of coagulation factors VIII & IX. The cascade reactions ultimately form fibrin clots and prevent excess bleeding.
The “hospital” segment of the end-user will witness a remarkable CAGR in the global hemophilia treatment market during 2020–2026
The hospitals and clinics accounted for the maximum revenue share of the global market under the end-user segment in 2019. The “hospital” segment is projected to grow splendidly during the forecast period owing to the availability of technologically advanced equipment, experienced doctors, and trained staff. Apart from this, growing R&D activities in hospitals and government funding are also propelling the “hospital” segment for hemophilia treatment globally.
The Latin America and Asia Pacific hemophilia treatment markets will experience flourishing growth in the coming years
In the coming years, the hemophilic patient pool is going to expand in the Asia Pacific & Latin America regions, which is one of the key opportunities for the regional players associated with hemophilia treatment. Moreover, the availability of technologically advanced equipment & methods for hemophilia treatment along with the development of better & precise diagnostic tools is propelling the hemophilia treatment market at a significant rate in these two regions.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 14,000 Million |
Projected Market Size in 2026 |
USD 35,000 Million |
CAGR Growth Rate |
15% CAGR |
Base Year |
2019 |
Forecast Years |
2020–2026 |
Key Market Players |
BioMarin Pharmaceutical Inc., Novo Nordisk, CSL Behring, Shire Plc., Pfizer Inc., Biogen, Bayer Healthcare, Chugai Pharmaceutical Co., and Baxalta, among others. |
Key Segment |
By Product, By Type, By Therapy,By Treatment, By End-User, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the key players driving the global hemophilia treatment market are BioMarin Pharmaceutical Inc., Novo Nordisk, CSL Behring, Shire Plc., Pfizer Inc., Biogen, Bayer Healthcare, Chugai Pharmaceutical Co., and Baxalta, among others.
This report segments the global hemophilia treatment market as follows:
Global Hemophilia Treatment Market: Product Segmentation Analysis
- Desmopressin
- Antifibrinolytic Agents
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Plasma-Derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor XIII
- Activated Prothrombin Complex Concentrate
- Von Willebrand Factor
Global Hemophilia Treatment Market: Type Segmentation Analysis
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Global Hemophilia Treatment Market: Therapy Segmentation Analysis
- Gene Therapy
- Antibody Therapy
- Replacement Therapy
- Immune Tolerance Induction (ITI) Therapy
Global Hemophilia Treatment Market: Treatment Segmentation Analysis
Global Hemophilia Treatment Market: End-User Segmentation Analysis
- Ambulatory Surgical Centres
- Hospitals
- Clinics
- Others
Global Hemophilia Treatment Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
Global Headquarters
Level 8, International Finance Center, Tower 2,
8 Century Avenue, Shanghai,
Postal - 200120, China
Tel: +86 21 80360450
Email: [email protected]
Web: https://www.fnfresearch.com
